Ulla Engetrom

Title: Ulla Engetrom: Innovator in Cancer Research

Introduction

Ulla Engetrom is a prominent inventor based in Uppsala, Sweden. She has made significant contributions to the field of cancer research, particularly through her innovative work on the Smad2 protein. Her research focuses on the mechanisms of phosphorylation and the interactions of Smad2 with other proteins, which are crucial for understanding cancer pathways.

Latest Patents

Ulla Engetrom holds a patent titled "Smad2 phosphorylation and interaction with Smad4." This invention describes the amino acid residues of the Smad2 protein that are important for its phosphorylation and activity. The patent includes Smad2 polypeptide fragments and biologically functional variants, including dominant-negative variants of Smad2 and related antibodies. Additionally, it covers nucleic acids that encode such variants and methods for utilizing these nucleic acids and polypeptides.

Career Highlights

Ulla Engetrom is affiliated with the Ludwig Institute for Cancer Research Limited, where she continues her groundbreaking research. Her work has been instrumental in advancing the understanding of cancer biology and therapeutic approaches.

Collaborations

Ulla has collaborated with notable researchers in her field, including Kiyoshi Tamaki and Ester Piek. These collaborations have further enriched her research and contributed to the advancement of cancer studies.

Conclusion

Ulla Engetrom's innovative contributions to cancer research through her patent on Smad2 phosphorylation highlight her role as a leading inventor in the scientific community. Her work continues to pave the way for new insights and potential therapies in cancer treatment.